Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XQZL001: cetuximab + FOLFIRI + NK cells as second-line treatment for metastatic KRAS wild-type colorectal cancer
ChiCTR-ONC-13004323Phase 4Completed
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab, irinotecan, fluorouracil, folinic acid and NK cell therapy (Anhui Provincial Hospital) in colorectal cancer (CRC), sponsored by Xinqiao Hospital. Primary endpoints: Disease control rate and Objective response rate. Started Apr 2014; status: completed.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acidNK cell therapy (Anhui Provincial Hospital)
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-ONC-13004323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13004323.